Inhibikase Therapeutics, Inc. Increase (Decrease) in Prepaid Expenses, Other
Inhibikase Therapeutics, Inc. (IKT) reported Increase (Decrease) in Prepaid Expenses, Other of $667.36 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpensesOther · last filed 2022-03-31
- Inhibikase Therapeutics, Inc. increase (decrease) in prepaid expenses, other for fiscal 2021 was $667.36K.
- Inhibikase Therapeutics, Inc. increase (decrease) in prepaid expenses, other for fiscal 2020 was $0.00.
| Period end | Increase (Decrease) in Prepaid Expenses, Other 12 month |
|---|---|
| 2021-12-31 | $667.36K 10-K · filed 2022-03-31 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |